Prothena Co. PLC Company Profile (NASDAQ:PRTA)

About Prothena Co. PLC (NASDAQ:PRTA)

Prothena Co. PLC logoProthena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PRTA
  • CUSIP: N/A
  • Web: www.prothena.com
Capitalization:
  • Market Cap: $1.97 billion
  • Outstanding Shares: 38,020,000
Average Prices:
  • 50 Day Moving Avg: $53.34
  • 200 Day Moving Avg: $53.75
  • 52 Week Range: $33.53 - $68.18
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.52
  • P/E Growth: 0.67
Sales & Book Value:
  • Annual Revenue: $1.05 million
  • Price / Sales: 1,878.55
  • Book Value: $13.07 per share
  • Price / Book: 3.97
Profitability:
  • EBIDTA: ($157,960,000.00)
  • Net Margins: -11,365.41%
  • Return on Equity: -32.65%
  • Return on Assets: -29.13%
Debt:
  • Current Ratio: 11.26%
  • Quick Ratio: 11.26%
Misc:
  • Average Volume: 302,211 shs.
  • Beta: 2.52
  • Short Ratio: 16.79
 

Frequently Asked Questions for Prothena Co. PLC (NASDAQ:PRTA)

What is Prothena Co. PLC's stock symbol?

Prothena Co. PLC trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena Co. PLC's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) issued its earnings results on Tuesday, May, 9th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.32) by $0.33. The business had revenue of $0.26 million for the quarter, compared to analysts' expectations of $0.26 million. Prothena Co. PLC had a negative return on equity of 32.65% and a negative net margin of 11,365.41%. The company's quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.81) EPS. View Prothena Co. PLC's Earnings History.

Where is Prothena Co. PLC's stock going? Where will Prothena Co. PLC's stock price be in 2017?

12 brokers have issued 1 year target prices for Prothena Co. PLC's shares. Their forecasts range from $65.00 to $95.00. On average, they expect Prothena Co. PLC's share price to reach $77.00 in the next year. View Analyst Ratings for Prothena Co. PLC.

What are analysts saying about Prothena Co. PLC stock?

Here are some recent quotes from research analysts about Prothena Co. PLC stock:

  • 1. According to Zacks Investment Research, "The narrower-than-expected loss in the first quarter was encouraging. Prothena’s efforts on developing its pipeline are encouraging. The company's elicense agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive. The collaboration not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments.The company’s shares have outperformed the Medical/Biomedical Genetics industry in the past one year. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates." (5/15/2017)
  • 2. Cantor Fitzgerald analysts commented, "Sticking to their knitting. In prior experience, PRTA scientists developed monoclonal antibodies (MAbs) bapineuzumab and natalizumab (Tysabri) that targeted misfolded protein (beta amyloid) and prevented T cell trafficking, respectively." (4/12/2017)
  • 3. Instinet analysts commented, "We are initiating on Prothena Corporation (PRTA) with a Buy rating and an $87 target price. We recommend owning PRTA shares ahead of Phase 2b PRONTO trial readout expected in early 2018 for lead asset NEOD001 in AL amyloidosis (a >$1.5bn peak sales opportunity). We view the pullback from 2016 highs and recent lows as an opportunity to accumulate the shares ahead of PRONTO data. Positive results from PRONTO based on change in NT-proBNP, a biomarker that NEOD001 substantially moved, yielding 53% responder rate in an early Phase 1/2b, are likely to support a conditional approval in the EU by 2019. In addition, we expect biomarker data from the PRX003 Phase 1b study to define mechanistically the breadth opportunity for MCAM/Th17-cell targeting in autoimmune disease, a potential multibillion dollar opportunity that, in our view, will raise the floor on PRTA's valuation. PRX002 could become a strong driver of PRTA's valuation in out years; however, given few near-term catalysts, it is unlikely to be a driver for PRTA shares in the next 12 months." (3/1/2017)

Who are some of Prothena Co. PLC's key competitors?

Who owns Prothena Co. PLC stock?

Prothena Co. PLC's stock is owned by a number of of retail and institutional investors. Top institutional investors include Woodford Investment Management Ltd (31.71%), FMR LLC (16.16%), Wellington Management Group LLP (9.02%), BlackRock Inc. (7.80%), State Street Corp (3.05%) and Palo Alto Investors LLC (3.01%). Company insiders that own Prothena Co. PLC stock include Arthur W Homan, Christopher S Henney, Dale B Schenk, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Lars Ekman, Martin Koller, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena Co. PLC.

Who sold Prothena Co. PLC stock? Who is selling Prothena Co. PLC stock?

Prothena Co. PLC's stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Morgan Stanley, Wells Fargo & Company MN, UBS Group AG, Pinnacle Associates Ltd., State Street Corp, American Century Companies Inc. and Turner Investments LLC. Company insiders that have sold Prothena Co. PLC stock in the last year include Arthur W Homan, Dennis J Selkoe, Gene G Kinney and Karin L Walker. View Insider Buying and Selling for Prothena Co. PLC.

Who bought Prothena Co. PLC stock? Who is buying Prothena Co. PLC stock?

Prothena Co. PLC's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Woodford Investment Management Ltd, FMR LLC, Redmile Group LLC, Wellington Management Group LLP, Loomis Sayles & Co. L P, Vanguard Group Inc. and Palo Alto Investors LLC. View Insider Buying and Selling for Prothena Co. PLC.

How do I buy Prothena Co. PLC stock?

Shares of Prothena Co. PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Prothena Co. PLC stock cost?

One share of Prothena Co. PLC stock can currently be purchased for approximately $51.88.

Analyst Ratings

Consensus Ratings for Prothena Co. PLC (NASDAQ:PRTA) (?)
Ratings Breakdown: 12 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $77.00 (48.42% upside)

Analysts' Ratings History for Prothena Co. PLC (NASDAQ:PRTA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017BTIG ResearchInitiated CoverageBuy$80.00HighView Rating Details
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMediumView Rating Details
5/11/2017Oppenheimer Holdings Inc.Set Price TargetBuy$70.00LowView Rating Details
4/12/2017Cantor FitzgeraldInitiated CoverageOverweight$86.00HighView Rating Details
4/3/2017WedbushReiterated RatingOutperform$77.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$87.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/20/2016SunTrust Banks, Inc.Initiated CoverageBuy$75.00N/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$73.00N/AView Rating Details
9/27/2016Credit Suisse Group AGReiterated RatingBuy$65.00N/AView Rating Details
8/4/2016Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00N/AView Rating Details
7/18/2016Royal Bank of CanadaReiterated RatingOutperform$95.00N/AView Rating Details
6/19/2015Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$49.00 -> $57.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Prothena Co. PLC (NASDAQ:PRTA)
Earnings by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
Earnings History by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($1.32)($0.99)$0.26 million$0.26 millionViewN/AView Earnings Details
2/14/2017Q416($1.12)($1.41)$5.35 million$0.20 millionViewListenView Earnings Details
11/1/2016Q3($1.22)($1.26)$0.49 million$0.29 millionViewN/AView Earnings Details
8/2/2016Q2($0.91)($1.18)$0.39 million$0.33 millionViewN/AView Earnings Details
5/3/2016Q116($0.77)($0.81)$0.27 million$0.27 millionViewN/AView Earnings Details
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details
11/2/2015($0.66)($0.73)$0.28 million$0.43 millionViewN/AView Earnings Details
8/4/2015Q2($0.56)($0.59)$0.60 million$0.28 millionViewN/AView Earnings Details
5/5/2015($0.59)($0.55)$1.95 million$0.59 millionViewN/AView Earnings Details
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details
8/4/2014Q214$0.06$15.17 million$15.12 millionViewN/AView Earnings Details
5/5/2014$0.81$0.78$30.17 million$32.23 millionViewN/AView Earnings Details
3/6/2014Q113($0.52)ViewN/AView Earnings Details
3/28/2013Q412($0.82)$0.13 million$0.58 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Prothena Co. PLC (NASDAQ:PRTA)
2017 EPS Consensus Estimate: ($5.07)
2018 EPS Consensus Estimate: ($5.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.42)($1.28)($1.36)
Q2 20173($1.20)($0.50)($0.94)
Q3 20173($1.62)($0.74)($1.23)
Q4 20173($1.96)($1.26)($1.54)
Q1 20181($1.39)($1.39)($1.39)
Q2 20181($1.36)($1.36)($1.36)
Q3 20181($1.18)($1.18)($1.18)
Q4 20181($1.07)($1.07)($1.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Prothena Co. PLC (NASDAQ:PRTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Prothena Co. PLC (NASDAQ:PRTA)
Insider Ownership Percentage: 3.70%
Insider Trades by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
Institutional Ownership by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
Insider Trades by Quarter for Prothena Co. PLC (NASDAQ:PRTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017Karin L WalkerInsiderSell5,000$52.25$261,250.00View SEC Filing  
4/3/2017Dennis J SelkoeDirectorSell3,500$55.86$195,510.00View SEC Filing  
3/9/2017Tran NguyenCFOBuy1,000$51.32$51,320.00View SEC Filing  
1/4/2017Arthur W HomanInsiderSell3,125$52.25$163,281.25View SEC Filing  
11/28/2016Dennis J SelkoeDirectorSell5,000$62.42$312,100.00View SEC Filing  
11/9/2016Gene G KinneyInsiderSell8,548$55.32$472,875.36View SEC Filing  
10/21/2016Gene G KinneyInsiderSell20,619$55.10$1,136,106.90View SEC Filing  
10/13/2016Karin L WalkerInsiderSell5,000$54.23$271,150.00View SEC Filing  
9/19/2016Karin L WalkerInsiderSell12,000$61.10$733,200.00View SEC Filing  
9/1/2016Arthur W HomanInsiderSell3,125$52.16$163,000.00View SEC Filing  
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.50View SEC Filing  
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.00View SEC Filing  
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.00View SEC Filing  
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.00View SEC Filing  
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.50View SEC Filing  
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00View SEC Filing  
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.00View SEC Filing  
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.25View SEC Filing  
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.00View SEC Filing  
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.00View SEC Filing  
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.00View SEC Filing  
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.00View SEC Filing  
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.00View SEC Filing  
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Prothena Co. PLC (NASDAQ:PRTA)
Latest Headlines for Prothena Co. PLC (NASDAQ:PRTA)
Source:
DateHeadline
americanbankingnews.com logo Brokerages Expect Prothena Co. PLC (PRTA) Will Post Quarterly Sales of $8.52 Million
www.americanbankingnews.com - May 26 at 1:32 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Research Coverage Started at BTIG Research
www.americanbankingnews.com - May 19 at 7:42 AM
americanbankingnews.com logoProthena Co. PLC (PRTA) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - May 17 at 7:50 PM
nasdaq.com logoProthena Announces Appointment of Sarah Noonberg, MD, PhD as ... - Nasdaq
www.nasdaq.com - May 17 at 8:26 AM
finance.yahoo.com logoETFs with exposure to Prothena Corp. Plc : May 15, 2017
finance.yahoo.com - May 15 at 6:35 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 15 at 2:46 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 15 at 12:22 PM
finance.yahoo.com logoProthena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : May 15, 2017
finance.yahoo.com - May 15 at 9:48 AM
americanbankingnews.com logoEquities Analysts Offer Predictions for Prothena Co. PLC's Q2 2017 Earnings (PRTA)
www.americanbankingnews.com - May 15 at 7:30 AM
americanbankingnews.com logoProthena Co. PLC (PRTA) Forecasted to Earn Q2 2017 Earnings of ($1.20) Per Share
www.americanbankingnews.com - May 15 at 7:28 AM
americanbankingnews.com logoProthena Co. PLC (PRTA) Given a $70.00 Price Target at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 13 at 6:58 PM
finance.yahoo.com logoProthena Corp. Plc :PRTA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 8:07 PM
americanbankingnews.com logoAnalysts Offer Predictions for Prothena Co. PLC's Q2 2017 Earnings (PRTA)
www.americanbankingnews.com - May 12 at 8:35 AM
seekingalpha.com logoProthena EPS of -$0.99
seekingalpha.com - May 12 at 12:51 AM
americanbankingnews.com logoSunTrust Banks Equities Analysts Increase Earnings Estimates for Prothena Co. PLC (PRTA)
www.americanbankingnews.com - May 11 at 3:42 PM
americanbankingnews.com logoWedbush Reaffirms Outperform Rating for Prothena Co. PLC (PRTA)
www.americanbankingnews.com - May 11 at 10:10 AM
americanbankingnews.com logoProthena Co. PLC (PRTA) Announces Earnings Results
www.americanbankingnews.com - May 10 at 7:40 PM
finance.yahoo.com logoProthena Reports First Quarter 2017 Financial Results and Provides R&D Update
finance.yahoo.com - May 9 at 6:53 PM
finance.yahoo.com logoProthena reports 1Q loss
finance.yahoo.com - May 9 at 6:53 PM
finance.yahoo.com logoProthena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : May 4, 2017
finance.yahoo.com - May 4 at 7:32 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Earning Somewhat Negative Press Coverage, Study Finds
www.americanbankingnews.com - May 2 at 5:26 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Expected to Announce Earnings of -$1.32 Per Share
www.americanbankingnews.com - May 1 at 9:00 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 8:36 AM
americanbankingnews.com logoProthena Co. PLC (PRTA) Receiving Somewhat Critical Press Coverage, Study Finds
www.americanbankingnews.com - April 28 at 2:50 PM
finance.yahoo.com logoProthena to Participate in the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - April 26 at 5:58 PM
finance.yahoo.com logoWhat to Expect from Prothena (PRTA) This Earnings Season?
finance.yahoo.com - April 26 at 5:58 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 26 at 2:46 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Earning Somewhat Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 25 at 7:49 PM
finance.yahoo.com logoProthena Corp. Plc – Value Analysis (NASDAQ:PRTA) : April 24, 2017
finance.yahoo.com - April 24 at 6:12 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Earning Somewhat Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 22 at 11:59 AM
finance.yahoo.com logoProthena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : April 21, 2017
finance.yahoo.com - April 21 at 7:09 PM
americanbankingnews.com logoKarin L. Walker Sells 5,000 Shares of Prothena Co. PLC (PRTA) Stock
www.americanbankingnews.com - April 19 at 8:23 PM
americanbankingnews.com logoFavorable News Coverage Very Unlikely to Affect Prothena Co. PLC (PRTA) Stock Price
www.americanbankingnews.com - April 19 at 11:51 AM
americanbankingnews.com logoProthena Co. PLC (PRTA) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 18 at 1:32 PM
americanbankingnews.com logoPiper Jaffray Companies Begins Coverage on Prothena Co. PLC (PRTA)
www.americanbankingnews.com - April 18 at 8:09 AM
americanbankingnews.com logoProthena Co. PLC (PRTA) Earning Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - April 16 at 2:35 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Now Covered by Piper Jaffray Companies
www.americanbankingnews.com - April 13 at 11:14 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Given Media Impact Rating of 0.24
www.americanbankingnews.com - April 13 at 7:47 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Sees Significant Decline in Short Interest
www.americanbankingnews.com - April 12 at 6:20 PM
americanbankingnews.com logoProthena Co. PLC (PRTA) Research Coverage Started at Cantor Fitzgerald
www.americanbankingnews.com - April 12 at 4:36 PM
americanbankingnews.com logo Analysts Expect Prothena Co. PLC (PRTA) Will Announce Earnings of -$1.31 Per Share
www.americanbankingnews.com - April 10 at 2:28 PM
americanbankingnews.com logoOppenheimer Holdings Inc. Analysts Give Prothena Co. PLC (PRTA) a $70.00 Price Target
www.americanbankingnews.com - April 7 at 8:59 PM
finance.yahoo.com logoProthena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : April 6, 2017
finance.yahoo.com - April 7 at 12:02 PM
americanbankingnews.com logoInsider Selling: Prothena Co. PLC (PRTA) Director Sells 3,500 Shares of Stock
www.americanbankingnews.com - April 5 at 8:30 PM
americanbankingnews.com logoProthena Co. PLC Forecasted to Post Q1 2017 Earnings of ($1.39) Per Share (PRTA)
www.americanbankingnews.com - April 5 at 11:19 AM
americanbankingnews.com logoProthena Co. PLC (PRTA) Forecasted to Post Q1 2018 Earnings of ($1.60) Per Share
www.americanbankingnews.com - April 4 at 1:19 PM
americanbankingnews.com logoProthena Co. PLC's (PRTA) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - April 3 at 2:34 PM
finance.yahoo.com logoClinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease
finance.yahoo.com - April 2 at 11:09 AM
finance.yahoo.com logoProthena Corporation plc : Press Release
finance.yahoo.com - April 2 at 11:09 AM
feeds.benzinga.com logoClinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease
feeds.benzinga.com - April 2 at 9:16 AM

Social

Chart

Prothena Co. PLC (PRTA) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff